About James La Rossa

This author has not yet filled in any details.
So far James La Rossa has created 120 blog entries.

Cassipa Approved by FDA for Opioid Dependence

By |2018-09-12T15:28:07+00:00September 12th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

A new dosage strength of buprenorphine and naloxone sublingual film was approved recently by the Food and Drug Administration. Cassipa sublingual film, made by Teva Pharmaceuticals, is a 16 mg/4 mg dosage of buprenorphine and naloxone for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual film also is [...]

Seven-Year Analysis on Benzodiazepine Prescribing for Children, Adolescents, and Young Adults Showed Marked Increase

By |2018-08-09T08:01:59+00:00August 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Conclusions The overall increase in prevalence rates of BZD dispensations during the study period and the unexpectedly high proportion of individuals who were prescribed a BZD on a long-term basis at a young age indicate a lack of congruence with international and national guidelines. These findings highlight the need for [...]

An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome

By |2018-08-07T12:30:37+00:00August 7th, 2018|Articles In Press|

By Roland van Rensburg and Eric H. Decloedt Abstract Neuroleptic malignant syndrome is a rare, idiosyncratic emergency associated with exposure to dopamine antagonists, commonly antipsychotic drugs. The typical clinical picture consists of altered consciousness, muscular rigidity, fever, and autonomic instability. While the condition has generally been well described, the pathophysiology is still [...]

Alzheimer’s Agent, BAN2401, Shows Promise; Trial Design Hits Snag

By |2018-08-02T07:56:18+00:00August 2nd, 2018|Brief Bulletins from the Field, We Know Psychiatry|

A monoclonal antibody,BAN2401, that targets soluble amyloid-beta oligomers, slowed cognitive decline by up to 47% while clearing brain amyloid in 81% of patients with mild cognitive impairment and very mild Alzheimer’s disease, according to phase 2 study results. A joint venture with Esai and Biogen, BAN2401, is among the most promising [...]

Akathisia Induced by Abrupt Withdrawal of Risperidone: A Case Report

By |2018-08-02T12:16:42+00:00June 29th, 2018|Articles In Press|

By Gangaparameswari Soundarrajan, Bharti Chogtu Magazine, Vybhav Krishna, Avinash Kamath G, and Manisha murugesan Abstract Akathisia is a common movement disorder that occurs as a consequence of antipsychotic therapy. However, its occurrence secondary to risperidone withdrawal has been reported rarely. Reporting of such rare adverse event gains profound importance because changing the antipsychotics is very [...]

Exercise as a Treatment for Schizophrenia: a Review

By |2018-08-02T12:16:42+00:00June 29th, 2018|Articles In Press|

By Steven J. Girdler, Jamie E. Confino and Mary E. Woesner Abstract Schizophrenia is a mental disorder that is characterized by progressive cognitive impairment in areas of attention, working memory, and executive functioning. Although no clear etiology of schizophrenia has been discovered, many factors have been identified that contribute to the development [...]

Bipolar Medication, Lamictal, Linked with Serious Immune System Reaction

By |2018-06-29T07:28:14+00:00June 29th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

The Food and Drug Administration has issued a warning that the seizure and bipolar medication Lamictal (lamotrigine) can cause a rare but potentially life-threatening immune response. This life-threatening immune response, known as hemophagocytic lymphohistiocytosis (HLH), causes an uncontrolled immune response and can present as a persistent fever greater than 101° F. [...]

Effects of a depression-focused internet intervention in slot machine gamblers: A randomized controlled trial

By |2018-06-08T16:28:40+00:00June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

By Lara Bücker , Julia Bierbrodt, Iver Hand, Charlotte Wittekind, and Steffen Moritz Background Problematic and pathological gambling have been linked to depression. Despite a high demand for treatment and negative financial consequences, only a small fraction of problematic and pathological gamblers seek professional help. The existing treatment gap could be narrowed by providing [...]

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, Trial Shows, but Decline of Clinical Symptoms Still a Question

By |2018-06-08T08:10:58+00:00June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key enzyme called [...]